KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Financing Activities (2016 - 2025)

Boston Scientific's Cash from Financing Activities history spans 17 years, with the latest figure at -$184.0 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 185.98% year-over-year to -$184.0 million; the TTM value through Dec 2025 reached -$395.0 million, down 121.78%, while the annual FY2025 figure was -$395.0 million, 121.78% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$184.0 million at Boston Scientific, down from -$104.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.6 billion in Q1 2024 and bottomed at -$344.0 million in Q2 2022.
  • The 5-year median for Cash from Financing Activities is $1.5 million (2021), against an average of $39.0 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 17300.0% in 2022 before it skyrocketed 2373.91% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$8.0 million in 2021, then surged by 112.5% to $1.0 million in 2022, then skyrocketed by 1400.0% to $15.0 million in 2023, then soared by 1326.67% to $214.0 million in 2024, then crashed by 185.98% to -$184.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Cash from Financing Activities are -$184.0 million (Q4 2025), -$104.0 million (Q3 2025), and -$340.0 million (Q2 2025).